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ABSTRACT
Background: The Pascal is a semiautomated photo-
coagulator that delivers a pattern array of multiple burns
in a rapid predetermined sequence with a single foot
pedal depression. Each burn is reduced to 10 or 20 ms to
achieve this. The authors report their early experience
with this system.
Methods: 75 procedures done in 60 patients divided into
four groups—group A, patients undergoing panretinal
photocoagulation (PRP); group B, patients undergoing
focal or modified grid macular laser; group C, patients
undergoing macular grid and group D, patients undergoing
retinopexy—were retrospectively studied.
Results: 31/34 procedures in group A, 24/26 procedures
in group B, 5/7 procedures in group C and all eight
patients in group D had successful outcomes. Significantly
higher powers were required with the Pascal than with
conventional laser (p,0.001) in eyes that underwent PRP
and focal/modified grid macular treatment with both
systems. Single session PRP was successfully performed
in five patients, and five were successfully treated with a
macular grid using pattern arrays only. No adverse events
were noted.
Conclusion: Although the shorter pulse duration of the
Pascal necessitates the use of a higher power, it is not
associated with adverse effects. The results here suggest
that the Pascal photocoagulator is safe and effective, and
offer several potential advantages related to the brief
exposure time.
Laser photocoagulation remains the gold standard
in the treatment of many retinal vascular disorders.
Conventional photocoagulation using a single
application of laser energy per shot is usually
delivered as a 100–200 ms duration burn. The
Pascal (Pattern Scan Laser) Photocoagulator, which
received United States Food and Drug
Administration (FDA) clearance in 2005, semiau-
tomates the procedure by delivering, with a single
foot pedal depression, multiple laser burns in a
rapid predetermined sequence in the form of a
pattern array produced by a scanner. To achieve
this, the pulse duration of each burn is reduced to
10–20 ms. This retrospective pilot study aims to
discuss our early experience with this system and
to record the laser parameters, especially the power
needed to produce therapeutic burns.
METHODS
A retrospective case note review of patients who
underwent Pascal treatment at Manchester Royal
Eye Hospital between November 2006 and May
2007 was performed. Information was collected on
age, sex, indication, pre- and postprocedure best
corrected visual acuities (BCVA), need for sub-
tenon’s anaesthetic as well as outcome and
complications of treatment. Treatment parameters
including use of a pattern or single spot, type of
pattern, power, burn duration and number of
burns per session were noted. If the same eye had
been previously treated for the same indication
with one of our conventional single spot lasers
(HGM, Salt Lake City, UT and Litechnica,
Manchester, UK), the power, numbers of burns,
spot size and burn duration were recorded in an
effort to compare the settings needed with each
system.
Four groups were created: group A, patients
undergoing panretinal photocoagulation (PRP) for
proliferative diabetic retinopathy (PDR) and
ischaemic vein occlusions; group B, patients under-
going focal or modified grid macular laser for
macular oedema secondary to diabetic retinopathy
and branch retinal vein occlusion (BRVO); group
C, patients undergoing grid treatment for diffuse
diabetic macular oedema; and group D, patients
undergoing retinopexy for retinal breaks/degenera-
tions.
Moderate intensity burns producing retinal
blanching were used for PRP and retinopexy, while
macular burns were lighter. Treatment for Group
A was deemed successful if, at the latest follow-up
visit, neovascularisation had regressed, and no
further treatment was planned, for Groups B and
C if the macula was dry and the oedema had
resolved, and for Group D if the break/degenera-
tion was well surrounded on all sides with an
adequate reaction.
The Pascal is a 532 nm frequency-doubled
neodymium-doped yttrium aluminum garnet
(Nd:YAG) solid-state laser. It can deliver numerous
patterns including squares, arcs, full and subset
grids, the shapes and sizes of which are adjustable,
in addition to single spots. For PRP, the 363, 464
and 565 arrays were most commonly used, but in
four eyes, single spots were administered for the
entire PRP. Whether single spot or pattern array
setting was used was decided independently of
clinical findings. Prior to starting treatment, the
operator chose whether or not to use Pascal based
on their experience with the use of the new Pascal
system.
All burns were placed one burn width apart.
Subset grids and single spots were used for focal
macular oedema. The full macular grid pattern was
used for five patients with diffuse macular oedema
who had good fixation, but single spots were used
for the rest. A combination of the arc pattern and
single spots was used for retinopexy with arc radii
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200 mm spot size in air using a contact lens with a spot-size
magnification factor of 26 producing burns of approximately
350–400 mm on the retina. Macular photocoagulation was
performed using 10 ms exposures and a spot size of 100 mmi n
air which produced a (100 mm burn on the macula because a
contact lens with a spot-size magnification factor of 16 was
utilised. Laser uptake may vary within the same fundus due to
contact lens curvature, refraction, eye curvature and tissue
characteristics such as pigmentation, so power needs to be
varied as with conventional lasers until the desired burn
intensity is achieved. Though efforts were made to avoid
previous laser burns by adjusting the location of the arrays as
necessary or changing the array pattern, this could not always
be achieved. No obvious side effects resulted from this conduct.
Data were analysed using SPSS (Statistical Package for Social
Sciences V.13). Descriptive statistics were used to summarise
data and explore groups. Visual acuities (VA) were converted
from Snellen to logMar to explore changes in vision pre- to
postlaser using the Sign and Kruskal–Wallis tests. For those
patients in groups A or B who had both previous conventional
laser and Pascal, differences between laser parameters were
explored, particularly the power using T and Mann–Whitney U
tests. A two-tailed p value of less than 0.05 was considered
significant (0.95 level of confidence).
RESULTS
In the study period, 121 procedures were performed, but a
complete set of data was available in only 75 procedures done
on 60 patients, of whom 32 (53.3%) were male, and 28 (46.7%)
were female with a mean age of 58.9 years (SD 15.3, range 14–
86). VA did not differ significantly pre- to postprocedure
(p=0.359) in any group. There were 34 (45.3%) procedures in
group A, 26 (34.7%) in group B, seven (9.3%) in group C and
eight (10.7%) in group D (table 1).
Of the 34 Group A procedures, 29 (85.3%) were for PDR,
three (8.8%) for vein occlusions (fig 1), one (2.9%) for ocular
ischaemic syndrome and one (2.9%) for proliferative sickle
retinopathy (PSR). The average laser power, number of burns
and mean follow-up period for the whole of group A are listed in
table 1.
Of the 34 PRP procedures, 12 (35.3%) used only the Pascal
photocoagulator. For the remaining 22 (64.7%), the Pascal
episode was for additional fill-in PRP, as they had previously had
conventional laser photocoagulation, but this had not ade-
quately controlled the neovascularisation. This group therefore
allowed us to directly compare the laser power needed using a
100 ms burn for the conventional treatment with the laser
power needed for the same eye during the Pascal episode using a
20 ms burn. The average power with the conventional
photocoagulator for these 22 procedures was 235 mW (SD
57.2, range 170–400), and the mean number of burns was 738
(SD 231.2, range 320–1178). The Pascal parameters used for
these 22 procedures were as follows: mean power was 396 mW
(SD 100.2, range 250–750), and the mean number of burns was
1116 (SD 417.2, range 500–2063). The difference in powers used
with the conventional and the Pascal lasers for these 22 patients
was highly significant (p,0.001), being 396 mW for Pascal
compared with 235 mW for conventional laser. Though
not specifically looked at in this study, it was generally
Table 1 Analysis of Pascal parameters, visual acuity and outcomes by
group
Group A Group B Group C Group D
No. of procedures 34 26 7 8
Prelaser VA logMAR, mean (SD) 0.31 (0.23) 0.30 (0.24) 0.6 (0.61) 0.01 (0.19)
Snellen equivalent 6/12 6/12 6/24 6/6
Postlaser VA logMAR, mean
(SD)
0.30 (0.27) 0.22 (0.24) 0.53 (0.61) 0.01 (0.19)
Snellen equivalent 6/12 6/9 6/18 6/6
Pascal power (mW), mean (SD) 389 (93.6) 135 (36.6) 154 (32.9) 332 (105.5)
Pascal no. of burns, mean (SD) 1180
(460.7)
78 (45.3) 73 (33.8) 159 (102.2)
Average follow-up in weeks,
mean (SD)
10.8 (5.9) 9.8 (3.3) 8.0 (5.5) 6.3 (3.2)
Successful outcome 31/34 24/26 5/7 8/8
logMAR, logarithm of the minimal angle of resolution; VA, visual acuity.
Figure 1 Colour fundus photograph showing uniformly distributed and
homogeneous laser burns produced with the Pascal photocoagulation
system in a patient who underwent sectoral laser photocoagulation for
ischaemic branch retinal vein occlusion.
Figure 2 Red free fundus photographs of a macular grid applied using
the Pascal pattern in diffuse diabetic macular oedema. Notice the evenly
distributed burns.
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treating the peripheral retina in comparison with power used
posterior to the equator.
Similarly, in these 22 patients, the mean number of burns
given with Pascal (1116) was significantly greater than the
mean number of burns given with conventional laser (738)
(p=0.004). Of these 22 procedures, 19 were successful with
regression of neovascularisation at their latest follow-up visit.
Three eyes needed further laser. Three patients had needed a
subtenon’s anaesthetic for their conventional laser session, but
none of them required it for their Pascal procedure.
Of the 12 PRP procedures done exclusively with the Pascal,
five (41.7%) were performed in a single session, and the rest
were fractionated into two episodes. The mean number of
burns given during single session PRP was 1498 (SD 592.7, range
508–2069). None of the eyes with single session PRP developed
any complications, and regression of neovascularisation was
noted in all, with no further treatment planned at their last
follow-up visit.
Group B included 26 procedures, of which three (11.5%) were
focal treatments for macular oedema secondary to BRVO, and
23 (88.5%) were focal treatments for diabetic CSME. The
average laser power, number of burns and mean follow-up
period for the whole of group B are in table 1. Ten (38.5%) eyes
had had previous focal macular laser in the same area using
conventional laser with an average power of 100 mW (SD 21.6,
range 70–140), spot size 50–100 mm and burn duration of 50–
100 ms. The mean number of burns was 88 (SD 76.6, range 15–
276). For those 10 patients who had previous conventional laser,
significantly higher powers were used for Pascal (143 mw) than
conventional (100 mw) (p,0.001) treatment. Following Pascal
treatment, in 24 of the 26 procedures, the macula was dry, and
no further laser was required. Two patients had residual CSME,
of which one underwent further laser, and one had intravitreal
triamcinolone acetonide injection (IVTA).
In Group C, there were seven eyes of six patients who
underwent a macular grid, five using the Pascal pattern (fig 2)
and two using single spots. The average laser power, number of
burns and mean follow-up period for the whole of group C are
listed in table 1. Two eyes did not achieve resolution of macular
oedema and underwent IVTA injection.
Retinopexy (fig 3) was done using the Goldman 3 mirror lens.
Application of an appropriately sized arc pattern was particu-
larly advantageous, as one entire edge of the break could be
sealed with a single footpedal depression as soon as a good view
was obtained, making the procedure quick and easy. The
treatment parameters are listed in table 1. All were successful
with adequate laser reaction all around, and none needed
further treatment.
Topical anaesthesia was sufficient in all groups, and none
required any other anaesthetic. No complications related to
laser treatment were noted in any patient. No effects were
observed on blood vessels if the array inadvertently involved a
retinal area traversed by blood vessels. None of the patients
experienced bleeding of either retinal or choroidal origin. No
effects were observed due to the operator being unable to avoid
old laser burns in re-treatments. The results here reported are
based on the data available. The procedures not included did not
seem to differ noticeably from those presented.
DISCUSSION
During photocoagulation, the aim is to optimise thermally
induced therapeutic effect but cause minimal retinal damage.
Laser–tissue interaction is influenced by wavelength, spot size,
power and exposure time. Retinal damage can be reduced by
changing some of these parameters. Pascal technology utilises
an exposure time of 10 ms for macular photocoagulation and
20 ms for PRP. Our experience reveals that this brief exposure
requires a higher power to achieve the desired therapeutic lesion.
Twenty-two eyes undergoing PRP in group A (n=34) under-
went photocoagulation with conventional laser and Pascal.
There was a highly statistically significant difference in the
mean power used between conventional laser (235 mW) and
Pascal laser (396 mW) (p,0.001). Similarly in group B, the
mean power used was significantly higher with the Pascal
system (143 mW) than with the conventional system
(100 mW) (p,0.001). A prospective case controlled randomised
clinical trial comparing laser parameters and outcomes between
two groups, one undergoing Pascal laser and the other a
conventional laser, would be the ideal way to highlight the
differences in power utilised by the two systems. Until these
results are available, our data give an indication of the higher
power settings needed with the Pascal system as compared with
conventional photocoagulation.
However, these higher power levels required with the Pascal
system did not result in any complications. This may be a
reflection of the reduced laser energy per burn reaching the eye
secondary to its shorter duration. Fluence is calculated as
power6time/area, and provided that spot size remains
unchanged, with a burn duration of 20 ms the fluence is less
than with a 100 ms burn when titrating to the same burn
intensity because of reduced diffusion of heat. In a histopatho-
logical study of rabbit eyes comparing the effects of various
pulse durations and powers, the power required to produce
ophthalmoscopically visible spots decreased with increasing
pulse duration, but the cumulative pulse energy increased with
pulse duration.
1 In conventional photocoagulation, a 400 mm
spot will produce a burn with a diameter greater than 400 mm,
whereas with a 20 ms pulse duration, the burn diameter will be
less than the spot diameter. While the energy per pulse is
reduced, the total energy delivered to the retina may be the
same because more spots must be delivered to compensate for
smaller burns.
There has been some concern that very short exposures may
cause acoustic shock wave damage and haemorrhage. Some
Figure 3 Retinopexy image.
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between retinal burn and retinal haemorrhage for pulse
durations less than 50 ms.
23It has been since then shown that
the point of change from thermomechanical cavitation-induced
RPE damage to pure thermal RPE denaturation occurs at a 50 ms
exposure time, a much shorter time than that employed by the
Pascal system. At pulse durations longer than 10 ms, pure
thermal denaturation of tissue is the primary retinal damage
mechanism.
45It is this thermal effect that produces therapeu-
tically desirable retinal lesions.
6 In the same histopathological
study of rabbit eyes cited above,
1 using pulse durations of
20 ms, the threshold for a visible burn was 110–120 mW, while
that for retinal haemorrhage was 600 mW, suggesting an
adequate safety margin. Another recent study on rabbit eyes
has demonstrated that 20 ms pulse durations represent an
optimal compromise between reduced collateral damage and
sufficient width of the therapeutic window.
7
Regression of neovascularisation is associated with greater
areas of retinal ablation at the initial treatment session.
8 The
mean number of burns used for single session PRP with the
Pascal was 1498, of which one patient had ischaemic BRVO
which needed only 508 burns. Resolution of neovascularisation
is significantly related to the cumulative total number of burns,
and successful photocoagulation requires considerably more
treatment than suggested by earlier studies.
9 With conventional
photocoagulators which deliver spot-by-spot treatment, this has
to be balanced against patient and operator discomfort
associated with the longer time required to achieve greater
retinal ablation per session. The array method of multiple burn
application allows for a larger area of retinal ablation in a
shorter time. However, although single-session PRP may be
possible with the Pascal system, its feasibility may be debatable
due to concerns such as macular oedema and exudative retinal
and choroidal detachments. In a small randomised trial by Doft
and Blankenship, these did occur more in the first few weeks
after single-session PRP, but the effects were transient, and no
long-term difference between single and multiple session
treatment groups was found.
10 In our patients, none who
underwent single-session PRP had any complications, but the
numbers were too small to draw a conclusion.
Longer burns may cause greater thermal diffusion, whereas
for short pulse durations, there is minimal diffusion of heat to
adjacent areas, resulting in localised homogenous burns.
11 This
may theoretically result in less discomfort. With topical
anaesthesia only, some patients find it difficult to tolerate
100 ms burns necessitating subtenon’s or peribulbar anaesthe-
sia.
12 In our series of patients, this was not required. Three
patients who had previously undergone PRP using 100 ms burns
required subtenon’s anaesthetic for those procedures but were
able to tolerate the Pascal procedure with only topical
anaesthesia. A recent study has shown that shortening the
exposure time to 20 ms is significantly less painful but equally
effective as conventional parameters.
13 Reducing the burn
duration combined with the application of a grid pattern has
the potential of reducing overall treatment duration, thereby
reducing costs to both hospitals and patients. Due to the
retrospective nature of our study, actual treatment times and
pain analogue scales were not available for analysis, but
prospective studies are under way in our unit to evaluate the
same.
This study, being retrospective and non-randomised has
limitations but justifies the need for prospective larger trials
comparing the Pascal technique with conventional lasers.
Innovative methods of improving upon the precision, safety,
comfort and efficiency of photocoagulation procedures are
welcome, and our early experience seems to indicate that the
Pascal method can offer this opportunity.
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